[The reasons for the application of endolymphatic therapy in the treatment of purulent lung diseases, complicated by empyema of the pleura].
Klaforan pharmacodynamics was studied up in pleural exudate and blood serum of the patients with purulent-destructive pulmonary diseases after its single endolymphatic and intravenous introduction in the dose 60 mg/kg of the body mass. Convalescence frequency in control group was 61.6%, in principal-82.9%, lethality-18.6 and 9.3% accordingly.
Pristaĭko
Ia I
IaI
Institut ftiziatrii i pul'monologii im. F.G. Ianovskogo AMN Ukrainy, g. Kiev.
Feshchenko
Iu I
IuI
Opanasenko
N S
NS
D000293:Adolescent; D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D016724:Empyema, Pleural / Q000150:complications*; D005260:Female; D006801:Humans; D007272:Injections, Intralymphatic; D008171:Lung Diseases / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013492:Suppuration / Q000473:pathology
D002511:Cephalosporins; D002439:Cefotaxime